There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Ionis Pharmaceuticals Inc. (IONS) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.39, or -1.11%, to $34.61. The Ionis Pharmaceuticals Inc. has recorded 21,267 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $35.00 and fluctuated between $35.03 as its day high and $33.64 as its day low. The current market capitalization of Ionis Pharmaceuticals Inc. is $5.12B. A total of 0.84 million shares were traded on the day, compared to an average of 967.23K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, IONS has seen 19 BUY and 20 SELL insider trades, representing the acquisition of 259,993 and the disposition of 118,601 shares. Over the last 12 months, there were 45 BUYs and 29 SELLs from insiders. Insiders purchased 364,609 shares during that period but sold 130,024.
In the most recent transaction, Monia Brett P sold 24,651 shares of IONS for 40.69 per share on Feb 06. After the transaction, the Chief Executive Officer now owns 145,305 company shares. In a previous transaction on Feb 06, HOUGEN ELIZABETH L sold 2,079 shares at 40.59 per share. IONS shares that EVP, Finance & CFO owns now total 75,496.
Among the insiders who sold shares, O’NEIL PATRICK R. disposed of 1,920 shares on Feb 06 at a per-share price of $40.86. This resulted in the EVP CLO & General Counsel holding 41,581 shares of IONS after the transaction. In another insider transaction, Geary Richard S sold 1,920 shares at $40.66 per share on Feb 06. Company shares held by the EVP, Chief Development Officer now total 72,385.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for IONS in the last 3 months, the mean price target is $49.86 with high estimates of $92.00 and low estimates of $24.00. In terms of 52-week highs and lows, IONS has a high of $48.82 and a low of $31.46.
As of this writing, IONS has an earnings estimate of -$0.9 per share for the current quarter. EPS was calculated based on a consensus of 14 estimates, with a high estimate of $0.11 per share and a lower estimate of -$1.53. The company reported an EPS of -$0.74 in the last quarter, which was -19.40% lower than expectations of -$0.62.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 23 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IONS is Sell with a score of 3.53. A total of 11 analysts rated the stock as Buy while 1 rated it as Overweight while 7 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 3 thought it should be Sold.